Boston Scientific Corporation (BSX)

Over the past six months, Boston Scientific's stock price has been impacted by several events. In July 2025, the company raised its annual profit forecast due to strong demand for heart devices, leading to a 4.8% share increase. In April 2025, shares rose 4.1% after a strong quarterly performance, driven by cardiovascular and electrophysiology sales. Between December 2025 and January 2026, Boston Scientific announced an agreement to acquire Valencia Technologies Corporation and participated in the J.P. Morgan Healthcare Conference. As of January 13, 2026, BSX stock was up 3.83% over the past 30 days and 1.17% over the past 12 months, trading above its 50-day and 200-day moving averages.

Boston Scientific's products and services generally experience steady quarterly demand, particularly for key cardiovascular devices like Watchman and Farapulse. The company's growth is supported by improvements in hospital staffing and healthy procedural volumes. Demand appears to be more influenced by factors like surgical procedure volumes and product adoption driven by clinical results and expanded indications, rather than strong seasonal fluctuations.

Boston Scientific Corporation (BSX) is an American biotechnology and biomedical engineering firm specializing in less-invasive medical devices. The company operates within the medical device industry and is structured around three global reportable segments: Cardiovascular, Rhythm and Neuro, and MedSurg. The Cardiovascular segment includes Interventional Cardiology and Peripheral Interventions, featuring products like drug-eluting stents and technologies for various vascular diseases. The Rhythm and Neuro segment comprises Cardiac Rhythm Management, Electrophysiology, and Neuromodulation, offering implantable devices for heart monitoring and neurological conditions. The MedSurg segment includes Endoscopy, Urology, and Pelvic Health, providing devices for diagnosing and treating gastrointestinal, urological, and pelvic conditions.

Boston Scientific has a significant global presence with approximately 53,000 employees across six continents. The company's global corporate headquarters are in Marlborough, Massachusetts, USA, with regional headquarters in Singapore and Paris. Boston Scientific operates 13 manufacturing facilities worldwide and has major technology centers in Minnesota, California, Ireland, and Costa Rica. The company also has 9 Institutes for Advancing Science located in the Americas, Africa, Asia, and Europe. In 2023, the company reported operational net sales growth across various regions: 10.4% in the United States, 12.9% in Europe, Middle East and Africa (EMEA), 19.1% in Asia Pacific (APAC), and 16.9% in Latin America and Canada (LACA).

Boston Scientific has consistently maintained a strong brand reputation and has been recognized on Fortune's list of the World's Most Admired Companies for eight consecutive years, including 2023. This recognition is based on attributes like leadership, innovation, quality, social responsibility, and workplace culture. The company's commitment to clinical excellence and collaborations with top physicians and academic institutions contribute to its reputation. No specific negative events significantly impacting Boston Scientific's brand reputation in the past year (January 2025 - January 2026) were found in the provided search results.

Boston Scientific Corporation's ownership is predominantly institutional, with institutional investors owning 82% of the company's shares. The top 10 institutional investors own 45%. Retail investors and insiders own approximately 18% of the company. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Fmr LLC (Fidelity Investments), and State Street Corp. Promerica LP is the largest individual shareholder, owning 3.69% of the company.